Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCND1
REST API REST API
Homo sapiens
CCND1 is differentially expressed in 335 experiments: 158 organism parts: lung, prostate, ... (156 more);, 265 disease states: normal, prostate carcinoma, ... (263 more);, 105 cell types 501 cell lines 53 compound treatments and 78 other conditions.
Synonyms D11S287E, BCL1, PRAD1, U21B31
Orthologs F1NS84_CHICK (Gallus gallus)   Ccnd1 (Mus musculus)   F6S8K9_CIOIN (Ciona intestinalis)   Ccnd1 (Rattus norvegicus)   CCND1_BOVIN (Bos taurus)   ccnd1 (Danio rerio)   CycD (Drosophila melanogaster)   ccnd1 (Xenopus laevis)   CCND1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cell division, cyclin-dependent protein kinase regulator activity, regulation of phosphorylation, protein binding, cytoplasm, intracellular, regulation of catalytic activity, positive regulation of cell proliferation, membrane, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, G1 phase of mitotic cell cycle, negative regulation of Wnt receptor signaling pathway, cell cycle, Wnt receptor signaling pathway, regulation of cell cycle, protein kinase binding, G1/S transition of mitotic cell cycle, nucleus, canonical Wnt receptor signaling pathway, kinase activity, response to drug, nucleoplasm, response to DNA damage stimulus, S phase of mitotic cell cycle, response to X-ray, endoplasmic reticulum unfolded protein response, response to ethanol, enzyme binding, protein kinase activity, response to corticosterone stimulus, mammary gland epithelial cell proliferation, response to magnesium ion, response to vitamin E, response to organic nitrogen, lactation, response to iron ion, response to calcium ion, positive regulation of mammary gland epithelial cell proliferation, fat cell differentiation, response to UV-A, re-entry into mitotic cell cycle, response to estrogen stimulus, organ regeneration, positive regulation of cyclin-dependent protein kinase activity, liver development, response to organic substance, negative regulation of epithelial cell differentiation, mammary gland alveolus development, cyclin-dependent protein kinase holoenzyme complex, response to steroid hormone stimulus, cellular response to organic substance, response to glucocorticoid stimulus, Leydig cell differentiation, protein phosphorylation, positive regulation of protein phosphorylation, mitotic cell cycle G1/S transition DNA damage checkpoint, response to organic cyclic compound
InterPro Term Cyclin-like, Cyclin_N, Cyclin_C, Cyclin_A/B/D/E
UniProt Accession P24385, Q9H014, Q6FI00, Q5MGB2, B4DR06, F5H6K6, F5H4R3, F5H437
Gene-Disease Assocation MYELOMA, MULTIPLE, COLORECTAL CANCER; CRC, VON HIPPEL-LINDAU SYNDROME; VHL, LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL
Search EB-eye ENSG00000110092
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SNU16
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
HL-60
2
E-GEOD-5258, E-GEOD-24147
Jurkat
2
E-GEOD-1880, E-MTAB-62
495 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-96
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
dendritic cell
1
2
E-MEXP-2019, E-GEOD-360, E-GEOD-3982
adipocyte
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
macrophage
1
2
E-GEOD-3982, E-GEOD-360, E-GEOD-8286
CD14+ monocyte
1
E-AFMX-5
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-3678, ... (63 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-GEOD-96, E-MTAB-62, E-MEXP-2034, E-GEOD-5377, E-MTAB-37, ... (6 experiments)
colon carcinoma
3
E-MTAB-37, E-MTAB-57, E-MTAB-62
neuroblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-1825
glioblastoma
2
E-MTAB-37, E-GEOD-6014
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-96
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
259 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-697, E-GEOD-3720, E-MEXP-1958, ... (33 experiments)

Factor Value U/D Experiments
17beta-estradiol
3
2
E-GEOD-2292, E-GEOD-4006
AMP
1
1
E-MEXP-2285
Ethanol
1
E-MEXP-2417
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
unknown
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
47 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-3891, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-21589

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-20115, E-MEXP-1648, E-TABM-868, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-MEXP-1273, E-TABM-263, ... (14 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-2466, E-MEXP-1956, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.316 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM